MARKET

VRAY

VRAY

Viewray
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.930
-0.270
-8.44%
After Hours: 2.930 0 0.00% 16:01 05/18 EDT
OPEN
3.080
PREV CLOSE
3.200
HIGH
3.150
LOW
2.880
VOLUME
1.42M
TURNOVER
641.92K
52 WEEK HIGH
8.25
52 WEEK LOW
2.390
MARKET CAP
528.74M
P/E (TTM)
-4.5349
1D
5D
1M
3M
1Y
5Y
Insider Buying Remains Elevated For A Second Week $SBUX $UBER $RILY
In an unusually volatile week, we saw significant market weakness earlier in the week probably driven by forced selling and a relief rally in the end. Insiders once again stepped up their purchases to take advantage of prices, which in some cases are down ...
Benzinga · 2d ago
Scott Drake Is The President of ViewRay, Inc. (NASDAQ:VRAY) And They Just Picked Up 7.5% More Shares
Investors who take an interest in ViewRay, Inc. ( NASDAQ:VRAY ) should definitely note that the President, Scott Drake...
Simply Wall St. · 4d ago
Insider Buy: Viewray
MT Newswires · 6d ago
Cullinan Oncology, Concert Pharmaceuticals top healthcare gainers; Eargo, Senseonics lead losers' pack
Gainers: Cullinan Oncology (CGEM) +21%. Concert Pharmaceuticals (CNCE) +20%. Babylon Holdings (BBLN) +16%. Blue Water Vaccines (BWV) +14%.  ViewRay (VRAY) +10%. Losers: Eargo (EAR) -24%. Senseonics (SENS) -14%. Ascendis Pharma (ASND) -11%. Evaxion Biotech ...
Seekingalpha · 6d ago
The past three years for ViewRay (NASDAQ:VRAY) investors has not been profitable
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
Simply Wall St. · 05/11 11:51
Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022
ViewRay, Inc. (Nasdaq: VRAY) announced today the results of a study presented at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) titled, "MR-guided SBRT/Hypofractionated RT for Metastatic and Primary Ultracentral and Centra...
PR Newswire · 05/10 10:30
--Morgan Stanley Lowers ViewRay's Price Target to $4 From $7, Equalweight Rating Kept
MT Newswires · 05/09 11:39
MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting
ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), with nearly 40 presentations and posters highl...
PR Newswire · 05/06 04:01
More
No Data
Learn about the latest financial forecast of VRAY. Analyze the recent business situations of Viewray through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

57.14%Strong Buy
28.57%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VRAY stock price target is 7.43 with a high estimate of 10.00 and a low estimate of 4.000.
High10.00
Average7.43
Low4.000
Current 2.930
EPS
Actual
Estimate
-0.15-0.11-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 257
Institutional Holdings: 209.94M
% Owned: 116.34%
Shares Outstanding: 180.46M
TypeInstitutionsShares
Increased
71
16.99M
New
41
5.15M
Decreased
34
8.18M
Sold Out
16
2.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.89%
Healthcare Equipment & Supplies
-2.33%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Moore
President/Chief Executive Officer/Director
Scott Drake
Chief Financial Officer
Zachary Stassen
Chief Scientific Officer
James Dempsey
Director
Karen Prange
Independent Director
Caley Castelein
Independent Director
B. Kristine Johnson
Independent Director
Brian Roberts
Independent Director
Susan Schnabel
Independent Director
Phillip Spencer
Independent Director
Gail Wilensky
No Data
No Data
About VRAY
ViewRay, Inc. designs, manufactures and markets the ViewRay MRIdian. The MRIdian is a system that integrates radiation therapy with simultaneous magnetic resonance imaging (MRI). It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. MRIdian system is comprised of three components: the MRI system, the radiation delivery system and an integrated treatment planning and delivery software. MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRIdian also records the level of radiation dose that the treatment area has received. MRIdian employs MRI-based technology to provide real-time imaging of tumor from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. ViewRay Technologies, Inc. and ViewRay GmbH are its subsidiaries.

Webull offers kinds of Viewray Inc stock information, including NASDAQ:VRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRAY stock methods without spending real money on the virtual paper trading platform.